Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction

Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minim...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2021-01, Vol.137 (1), p.20-28
Main Authors: Sidhom, Iman, Shaaban, Khaled, Youssef, Sarah H., Ali, Nesreen, Gohar, Seham, Rashed, Wafaa M., Mehanna, Mai, Salem, Sherine, Soliman, Sonya, Yassin, Dina, Mansour, Emad, Coustan-Smith, Elaine, Ribeiro, Raul C., Rivera, Gaston K.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Child
Child, Preschool
Clinical Trials and Observations
Female
Humans
Infant
Male
Neoplasm, Residual - pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology
Remission Induction - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2020007977